Abstract:Pompe disease (PD) is a rare autosomal recessive lysosomal disorder caused by loss‐of‐function of the α‐glucosidase (GAA) gene. The deficient GAA enzyme activity may result in potential life‐threatening muscle weakness, thus requiring a rapid diagnosis to initiate therapeutic interventions. In this large retrospective study, we analyzed 30.836 PD suspect samples from 57 countries using a two‐step approach utilizing dried blood spots (DBSs): biochemical testing of GAA activity followed by complementary genetic sequencing of GAA in biochemically conspicuous cases. Of these 30.836 samples, 2% (n = 639) were excluded; accordingly, this study consisted of 30.193 cases. Biochemical testing of GAA enzyme activity showed normal values in 28.354 (93.90%) and enzyme activity below the cut‐off in 1843 (6.10%) cases. These biochemically suspicious cases were genetically analyzed. We identified 723 Pompe cases with 283 different GAA alterations, and 98 variants have been unpublished so far. The most common variant was the splice variant c.‐32‐13T>G (IVS1). Looking at the IVS1‐genotype, the majority was compound heterozygous (n = 169) and identified in late‐onset cases (n = 162). Comparison of early‐ versus late‐onset cases to evaluate whether certain genotypes correlate with the age of onset revealed that homozygosity was predominantly found in infantile (85.65%) and compound heterozygosity in late‐onset (76.9%) cases. Analysis of homozygous cases revealed 61% nonsense variants in the early stages and 87% missense variants in the late stages. Mapping of disease‐associated (homozygous) missense variants to functional GAA protein domains showed that missense variants were found throughout GAA, but we identified enrichment in the catalytic domain. A strict genotype–phenotype correlation cannot be established; nevertheless, a phenotypic implication of some GAA variants could be drawn (e.g., c.896T>C/p.L299P, c.2015G>A/p.R672Q, and c.‐32‐13T>G). The combined enzyme activity and genetic testing from DBS cards can reliably identify PD and significantly accelerate diagnosis. We identified new genetic variants that contribute to the spectrum of pathogenic variants of the GAA gene.

A Patient with the GLA p.E66Q Mutation Exhibiting Vascular Parkinsonism and Bilateral Pulvinar Lesions

Four novel rare mutations of PLA2G6 in Chinese population with Parkinson's disease.

Early-Onset Parkinson's Disease Caused by PLA2G6 Compound Heterozygous Mutation, a Case Report and Literature Review

Identification of a novel nonsense mutation in α-galactosidase A that causes Fabry disease in a Chinese family

Fabry disease caused by the GLA p.Gly183Asp (p.G183D) variant: Clinical profile of a serious phenotype

c.640–814 T > C mutation in deep intronic region of alpha-galactosidase A gene is associated with Fabry disease via dominant-negative effect

Elevation of gangliosides in four brain regions from Parkinson’s disease patients with a GBA mutation

Clinical features, genetic variations and enzyme replacement therapy in five Chinese patients with Fabry disease

[A Boy with Fabry Disease with the Onset at the Age of Four].

Dopaminergic neurodegeneration in Gerstmann-Sträussler-Scheinker (P102L) disease: insights from imaging and pathological examination

Previously Unidentified Gene Variation Associated with Fabry Disease: The Impact on One Family

GLA Mutations Suppress Autophagy and Stimulate Lysosome Generation in Fabry Disease

Novel α-galactosidase A gene mutation in a Chinese Fabry disease family: A case report

GAA gene mutation detection following clinical evaluation and enzyme activity analysis in Azeri Turkish patients with Pompe disease

A Chinese patient of P102L Gerstmann-Sträussler-Scheinker disease contains three other disease-associated mutations in SYNE1.

Functional and Biological Studies of Alpha-Galactosidase A Variants with Uncertain Significance from Newborn Screening in Taiwan

The loss of function GBA1 c.231C > G mutation associated with Parkinson disease

Biochemical and Genetic Testing of GAA in Over 30.000 Symptomatic Patients Suspected to Be Affected With Pompe Disease

Glucocerebrosidase Mutations Cause Mitochondrial and Lysosomal Dysfunction in Parkinson's Disease: Pathogenesis and Therapeutic Implications

A novel variant of PLA2G6 gene related early-onset parkinsonism: a case report and literature review

Novel GLA gene mutations in two Chinese families with classic Fabry disease